109 related articles for article (PubMed ID: 21687944)
1. Nuclear localization of phosphorylated ERK1 and ERK2 as markers for the progression of ovarian cancer.
Amsterdam A; Shezen E; Raanan C; Schreiber L; Prus D; Slilat Y; Ben-Arie A; Seger R
Int J Oncol; 2011 Sep; 39(3):649-56. PubMed ID: 21687944
[TBL] [Abstract][Full Text] [Related]
2. u-PA expression in benign, borderline and malignant ovarian tumors.
Kiziridou AD; Toliou T; Stefanou D; Agnantis N
Anticancer Res; 2002; 22(2A):985-90. PubMed ID: 12014682
[TBL] [Abstract][Full Text] [Related]
3. Two initiation sites of early detection of colon cancer revealed by localization of pERK1/2 in the nuclei or in aggregates at the perinuclear region of the tumor cells.
Amsterdam A; Shezen E; Raanan C; Schreiber L; Slilat Y; Fabrikant Y; Melzer E; Seger R
Acta Histochem; 2013 Jul; 115(6):569-76. PubMed ID: 23357054
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
5. Human ovarian tumors express gamma-glutamyl transpeptidase.
Hanigan MH; Frierson HF; Brown JE; Lovell MA; Taylor PT
Cancer Res; 1994 Jan; 54(1):286-90. PubMed ID: 7903206
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of hK6 expression with clinicopathological features and prognosis in epithelial ovarian cancer].
Hu CJ; Zhang F; Chen YJ; Sun XM; Zheng JF
Zhonghua Zhong Liu Za Zhi; 2009 Jul; 31(7):520-3. PubMed ID: 19950700
[TBL] [Abstract][Full Text] [Related]
7. Clinical factors and biomarkers in ovarian tumors development.
Vrabie CD; Petrescu A; Waller M; Dina I
Rom J Morphol Embryol; 2008; 49(3):327-38. PubMed ID: 18758637
[TBL] [Abstract][Full Text] [Related]
8. B7-H4 overexpression in ovarian tumors.
Tringler B; Liu W; Corral L; Torkko KC; Enomoto T; Davidson S; Lucia MS; Heinz DE; Papkoff J; Shroyer KR
Gynecol Oncol; 2006 Jan; 100(1):44-52. PubMed ID: 16256178
[TBL] [Abstract][Full Text] [Related]
9. Morphological subtypes of ovarian carcinoma: a review with emphasis on new developments and pathogenesis.
McCluggage WG
Pathology; 2011 Aug; 43(5):420-32. PubMed ID: 21716157
[TBL] [Abstract][Full Text] [Related]
10. Cyclooxygenase 2 expression in serous tumors of the ovary.
Singhal PK; Spiegel G; Driscoll D; Odunsi K; Lele S; Rodabaugh KJ
Int J Gynecol Pathol; 2005 Jan; 24(1):62-6. PubMed ID: 15626918
[TBL] [Abstract][Full Text] [Related]
11. Expression of cyclooxygenase-2 and inducible nitric oxide synthase in human ovarian tumors and tumor-associated macrophages.
Klimp AH; Hollema H; Kempinga C; van der Zee AG; de Vries EG; Daemen T
Cancer Res; 2001 Oct; 61(19):7305-9. PubMed ID: 11585770
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study.
Brustmann H
Gynecol Oncol; 2005 Sep; 98(3):396-402. PubMed ID: 16005054
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of stromal metalloproteinase-2 in ovarian adenocarcinoma and its relation to carcinoma progression.
Torng PL; Mao TL; Chan WY; Huang SC; Lin CT
Gynecol Oncol; 2004 Feb; 92(2):559-67. PubMed ID: 14766248
[TBL] [Abstract][Full Text] [Related]
14. Histological classification of ovarian cancer.
Kaku T; Ogawa S; Kawano Y; Ohishi Y; Kobayashi H; Hirakawa T; Nakano H
Med Electron Microsc; 2003 Mar; 36(1):9-17. PubMed ID: 12658347
[TBL] [Abstract][Full Text] [Related]
15. LMX1A as a prognostic marker in ovarian mucinous cystadenocarcinoma.
Lin CK; Chao TK; Lai HC; Lee HS
Am J Clin Pathol; 2012 Jun; 137(6):971-7. PubMed ID: 22586057
[TBL] [Abstract][Full Text] [Related]
16. Epiregulin as a marker for the initial steps of ovarian cancer development.
Amsterdam A; Shezen E; Raanan C; Slilat Y; Ben-Arie A; Prus D; Schreiber L
Int J Oncol; 2011 Nov; 39(5):1165-72. PubMed ID: 21769422
[TBL] [Abstract][Full Text] [Related]
17. The expression of six biomarkers in the four most common ovarian cancers: correlation with clinicopathological parameters.
Lin CK; Chao TK; Yu CP; Yu MH; Jin JS
APMIS; 2009 Mar; 117(3):162-75. PubMed ID: 19245589
[TBL] [Abstract][Full Text] [Related]
18. Significance of cell cycle regulatory proteins as malignant and prognostic biomarkers in ovarian epithelial tumors.
Lee YH; Heo JH; Kim TH; Kang H; Kim G; Kim J; Cho SH; An HJ
Int J Gynecol Pathol; 2011 May; 30(3):205-17. PubMed ID: 21464733
[TBL] [Abstract][Full Text] [Related]
19. [Correlation of DPPIV expression with clinicopathological features and prognosis in epithelial ovarian carcinoma].
Zhang MZ; Qiao YH; Suo ZH
Zhonghua Zhong Liu Za Zhi; 2008 Nov; 30(11):848-52. PubMed ID: 19173831
[TBL] [Abstract][Full Text] [Related]
20. Metallothionein expression and nuclear size in benign, borderline, and malignant serous ovarian tumours.
Tan Y; Sinniah R; Bay BH; Singh G
J Pathol; 1999 Sep; 189(1):60-5. PubMed ID: 10451489
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
